KILPATRICK STO



PTO/SB/51 (02-01) Approved for use through 01/31/2004. OMB 0651-0033 atent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are spond to a collection of information unless it displays a valid OMB control number

Docket Number (Optional) 13131-0110 (44378-232454)

REISSUE APPLICATION DECLARATION BY THE INVENTOR

As a below named inve	entor, I hereby d	eclare that:		
My residence, mailing	address and citiz	zenship are stated below ne	ext to my name.	
I believe I am the origin	nal, First and sol	e inventor (if only one name	e is listed below) o	or an original, first and
joint inventor (if plural	names are listed	below) of the subject matte	er which is describ	ed and claimed in
patent number 5,911,6	98, granted <u>Jun</u>	e 15, 1999, and for which a	reissue patent is	sought on the invention
entitled Treatment for	Cardiovascula	r and Related Diseases, th	ne specification of	which
is attached hereto	D .			
was filed on June	<u>• 12, 2001</u> as rei	ssue application number <u>05</u>	9/879,002.	
amended by any amer I acknowledge the duty	ndment referred to y to disclose info inal patent to be	entents of the above identification to above. In attention which is material to wholly or partly inoperative	patentability as d	efined in 37 CFR 1.56.
☐ by reason of a depleted by the depleted	efective specifica	tion or drawing.		
by reason of the i	patentee claimin	g more or less than he had	the right to claim i	n the patent.
by reason of othe	er errors.			
At least one error upor such must be stated w	n which reissue is ith an explanatio	s based is described below in as to the nature of the bro	If the reissue is a cadening:	a broadening reissue,
Independent claims 1 a	and 19 are respe	ectively too narrowly drawn	to comprise "the d	elipidated fraction is
recombined with the bl	ood cells and rel	turned to the subject."		
application(s) for patent application for patent or	or inventor's or inventor's certi	certificate listed below, ar	nd have also ide natter in common	19 (a)-(d) of the foreign entified below any foreign with the above-identified aimed:
Application No.	Country	Filing Date	Priority Claime	d Under 35 USC §119
· · · ————		- ———		-
PCT/AU95/00875	PCT	December 22, 1995	Yes <u>X</u>	No

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chiof Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/51 (02-01)

Approved for use through 01/31/2004. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Docket Number (Optional) (REISSUE APPLICATION DECLARATION BY THE 13131-0110 (44378-232454) INVENTOR, page 2) All errors corrected in this reissue application arose without any deceptive intention on the part of the applicant. As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith. Registration Number Name(s) Correspondence Address: Direct all communications about the application to: 冈 Customer Number 23370 Type Customer Number Here PATATOTE PARTITION OF THE PARTITION OF T Kilpatrick Stockton LLP 冈 Firm or Individual Name Suite 2800 Address 1100 Peachtree Street Address 30309 Zip State Georgia Atlanta City Country USA 404-815-6500 Fax 404-815-6555 Telephone I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this declaration is directed. Full name of sole or first inventor (given name, family name) Karim Rouan Cham 15 October 2001 Date Inventor's signature-Residence 27 Double Jump Redland Road, Bay Citizenship The Netherlands Queensland 4165, Australia Full name of second joint inventor (given name, family name) Bill Elliot Cham 15 Ochbar 2001 Date Inventor's signature Residence 365 Woodlands Drive, Sheldon Queensland Citizenship The Netherlands 4157, Australia Mailing Address Full name of sole or first inventor (given name, family name) Inventor's signature Inventor's signature Citizenship Residence

[Page 2 of 2]

Additional joint inventors are named on separately numbered sheets attached hereto.

Mailing Address





Patents

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applio	eation:)
Karim Rou	an Cham et al.)
Serial No.: Reissue	09/879,002 of U.S. Patent No. 5,911,698) Art Unit: 3735
Filed:	June 12, 2001)
For:	Treatment for Cardiovascular)

CONSENT OF ASSIGNEE FOR REISSUE UNDER 37 C.F.R. § 1.172

Assistant Commissioner for Patents Washington, D.C. 20231

Sirs:

Aruba International Pty. Ltd., an assignee of U.S. Patent No. 5,911,698, consents to the filing of Reissue Application No. 08/849,543 for the reissue of U.S. Patent No. 5,911,698.

8 Ochber 2001

Aruba International Pty. Ltd. 14/1645 Ipswich Rd.

Rocklea, Queensland 4106, Australia